Urinary KIM-1 Concentration Interpreted in Detecting AKI
|
By LabMedica International staff writers Posted on 25 Mar 2019 |

Image: The Urisys 2400 urine analyzer (Photo courtesy of Roche Diagnostics).
Kidney injury molecule-1 (KIM-1) has been identified as a biomarker for the assessment of nephropathy in various chronic kidney diseases (CKD). Extensive KIM-1 expression occurs in proximal tubule cells in patients with confirmed acute tubular necrosis.
Urinary KIM-1 concentrations were also significantly correlated with the expression of tissue KIM-1 in systemic lupus erythematosus patients. Such findings increase the potential use of urinary KIM-1 in the diagnosis or prognosis of CKD, but also results in the difficulties in the interpretation of urinary KIM-1 when it is used in the early detection of acute kidney injury (AKI).
Scientists collaborating with those at Queen’s University (Kingston, ON, Canada) obtained 188 urine samples were obtained from adults with normal kidney filtration. Of which 83 of the 188 showed negative urine protein, erythrocytes and leucocytes were used as normal controls. The remaining 105 samples showed at least one abnormal result suggesting possible pre-existing nephropathy.
Routine urine analysis was performed on an Urysis 2400 analyzer of the hospital core laboratory, using a multi-parameter test cassette that measures pH, protein (albumin), glucose, ketones, bilirubin, urobilinogen, nitrite, erythrocyte, leukocyte esterase, and specific gravity. The urinary KIM-1 concentrations were measured in duplicate for each sample using the Quantikine enzyme-linked immunosorbent assay (ELISA) kit. The limit of detection was 0.009μg/L.
The investigators reported that the results showed significantly increased urinary KIM-1 concentration in protein positive (protein +, erythrocyte +/-, leucocyte+/-) samples compared to controls that were negative for protein, erythrocytes, and leucocytes. Urinary KIM-1 concentrations were significantly higher when proteinuria was at trace concentration (0.25g/L) and correlated with the severity of proteinuria. The creatinine normalized urinary KIM-1 was significantly higher when urine protein was 0.75g/L to 5g/L. The reference interval for urinary KIM-1 was 0 to 4.19 μg/L, and for creatinine normalized urinary KIM-1 0 to 0.58 μg/mmol.
The authors concluded that baseline urinary KIM-1 concentrations were increased when there was detectable urine protein and correlated with its severity. The urinary KIM-1 concentrations should be interpreted with consideration of urine protein levels in individual patients. The study was published on March 7, 2019, in the journal Practical Laboratory Medicine.
Related Links:
Queen’s University
Urinary KIM-1 concentrations were also significantly correlated with the expression of tissue KIM-1 in systemic lupus erythematosus patients. Such findings increase the potential use of urinary KIM-1 in the diagnosis or prognosis of CKD, but also results in the difficulties in the interpretation of urinary KIM-1 when it is used in the early detection of acute kidney injury (AKI).
Scientists collaborating with those at Queen’s University (Kingston, ON, Canada) obtained 188 urine samples were obtained from adults with normal kidney filtration. Of which 83 of the 188 showed negative urine protein, erythrocytes and leucocytes were used as normal controls. The remaining 105 samples showed at least one abnormal result suggesting possible pre-existing nephropathy.
Routine urine analysis was performed on an Urysis 2400 analyzer of the hospital core laboratory, using a multi-parameter test cassette that measures pH, protein (albumin), glucose, ketones, bilirubin, urobilinogen, nitrite, erythrocyte, leukocyte esterase, and specific gravity. The urinary KIM-1 concentrations were measured in duplicate for each sample using the Quantikine enzyme-linked immunosorbent assay (ELISA) kit. The limit of detection was 0.009μg/L.
The investigators reported that the results showed significantly increased urinary KIM-1 concentration in protein positive (protein +, erythrocyte +/-, leucocyte+/-) samples compared to controls that were negative for protein, erythrocytes, and leucocytes. Urinary KIM-1 concentrations were significantly higher when proteinuria was at trace concentration (0.25g/L) and correlated with the severity of proteinuria. The creatinine normalized urinary KIM-1 was significantly higher when urine protein was 0.75g/L to 5g/L. The reference interval for urinary KIM-1 was 0 to 4.19 μg/L, and for creatinine normalized urinary KIM-1 0 to 0.58 μg/mmol.
The authors concluded that baseline urinary KIM-1 concentrations were increased when there was detectable urine protein and correlated with its severity. The urinary KIM-1 concentrations should be interpreted with consideration of urine protein levels in individual patients. The study was published on March 7, 2019, in the journal Practical Laboratory Medicine.
Related Links:
Queen’s University
Latest Immunology News
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
- New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
- Gene Signature Test Predicts Response to Key Breast Cancer Treatment
- Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
- Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
- Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
- Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection
- Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer
- Luminescent Probe Measures Immune Cell Activity in Real Time
- Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients
- Novel Tool Predicts Most Effective Multiple Sclerosis Medication for Patients
- Companion Diagnostic Test for CRC Patients Identifies Eligible Treatment Population
Channels
Molecular Diagnostics
view channel
Blood Metabolite Signature Test Better Predicts Type 2 Diabetes Risk
Type 2 diabetes is rising worldwide and now accounts for more than 90% of all diabetes cases, driven by impaired insulin response and long-term metabolic dysfunction. The disease often develops silently... Read more
Genetic Test Could Detect Predisposition to Pancreatic Cancer
Pancreatic ductal adenocarcinoma is one of the deadliest cancers, largely because it is usually diagnosed at an advanced stage when treatment options are limited. The lack of effective population screening... Read moreHematology
view channel
AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
Alpha thalassemia affects millions of people worldwide and is especially common in regions such as Southeast Asia, where carrier rates can reach extremely high levels. While the condition can have significant... Read more
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read moreImmunology
view channel
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
Antibiotic resistance is rising worldwide, threatening the effectiveness of treatments for major infectious diseases, including tuberculosis (TB). Resistance to key TB drugs, such as bedaquiline, is of... Read morePathology
view channel
Intraoperative Tumor Histology to Improve Cancer Surgeries
Surgical removal of cancer remains the first-line treatment for many tumors, but ensuring that all cancerous tissue is removed while preserving healthy tissue is a major challenge. Surgeons currently rely... Read more
Rapid Stool Test Could Help Pinpoint IBD Diagnosis
Inflammatory bowel disease (IBD) is a chronic condition in which the immune system mistakenly attacks the digestive tract, causing persistent gut inflammation. Diagnosis and disease monitoring often depend... Read more
AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery
Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
World Health Expo (WHX) Labs in Dubai (formerly Medlab Middle East), which will be held at Dubai World Trade Centre from 10-13 February, will address the growing global threat of antimicrobial resistance... Read more







